Dylan Davis supports life sciences clients with market access and reimbursement research and analysis that spans a range of healthcare sectors and stakeholders.

She applies her federal health experience in quantitative analysis and quality measures to help a broad span of clients.

Prior to joining Avalere, Dylan was a consultant at The Lewin Group. She performed quantitative analysis for the Oncology Care Model (OCM) evaluation and was the assistant project manager for the Development, Reevaluation, and Implementation of Outpatient Outcome Efficiency Measures project. She has extensive knowledge of OCM program rules, evaluation methods, and quality measure design and testing.

Dylan has a PhD and MS in cognitive neuroscience from the City University of New York and a BS in biomedical sciences from the University of Oklahoma.

Authored Content

Avalere and the Amputee Coalition analyzed claims data to understand the prevalence of limb loss and limb difference and the implications for public policy.

Among Medicare Fee-for-Service (FFS) beneficiaries, potential rare disease patients' residences have a median distance of over 200 miles to a relevant clinical trial site.

Uncertainty related to the Dobbs ruling could have downstream effects on reproductive healthcare that go beyond abortion.